PDS Biotech Faces Nasdaq Delisting Warning After Stock Dips Below $1.00

summarizeSummary

Nasdaq notified PDS Biotech on July 30, 2026, that its stock has fallen below the $1.00 minimum bid price, triggering a 180-day compliance period. The company may pursue a reverse stock split to avoid delisting.

check_boxKey Events · Legal and Risk Events · PDSB

• Nasdaq Deficiency Notice Received

  On July 30, 2026, PDS Biotech received a Nasdaq deficiency letter because its common stock closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement.

• 180-Day Compliance Window

  The company has until January 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. A second 180-day period may be available if certain conditions are met.

• Reverse Stock Split Under Consideration

  Management stated it may initiate a reverse stock split to cure the deficiency, though no assurance is given that compliance will be regained.

• Delisting Risk Looms

  If compliance is not achieved by the end of the applicable period(s), the stock will be subject to delisting from The Nasdaq Capital Market, though the company could appeal.

auto_awesomeAnalysis · PDSB · Life Sciences

Nasdaq has put PDS Biotech on notice after its stock closed below $1.00 for 30 consecutive business days. The company now has until January 26, 2027, to regain compliance — likely through a reverse stock split — or face delisting. This development arrives just two months after the company had resolved a prior bid-price deficiency, and against a backdrop of heavy dilution from a recently activated $50 million ATM program and a pending shareholder vote to double authorized shares. With the stock closing at $0.6861 today, well below the $1.00 threshold, a reverse split looks increasingly probable.